Regulations.gov document
Reference 3 - Niazi SK. Advice to the FDA to Improve Its Proposed Guidelines to…
Supporting & Related Material · FDA-2025-P-6763 · posted Dec 5, 2025
Key facts
| Document ID | FDA-2025-P-6763-0005 |
|---|---|
| Title | Reference 3 - Niazi SK. Advice to the FDA to Improve Its Proposed Guidelines to Rationalize Clinical Trials by Restricting Placebo Control, Preventing Low-Powered Studies, and Disallowing Studies Where Bioavailability Is Not Proven. Pharmaceuticals (Basel). 2024 Oct 24;17(11):1424. doi: 10.3390/ph17111424 |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2025-P-6763 |
| Posted | Dec 5, 2025 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: